Certolizumab pegol – new option in the treatment of psoriatic arthritis
It has been proven that tumor necrosis factor (TNF) plays an important role in the pathophysiology of psoriatic arthritis (PsA). TNF inhibitors have been demonstrated to improve the skin and joint manifestations of psoriasis. New possibilities of treatment of the disease have appeared due to availab...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Termedia Publishing House
2014-07-01
|
| Series: | Rheumatology |
| Subjects: | |
| Online Access: | http://www.termedia.pl/Certolizumab-pegol-new-option-in-the-treatment-of-psoriatic-arthritis,18,23171,1,1.html |
| Summary: | It has been proven that tumor necrosis factor (TNF) plays an important role in the pathophysiology of psoriatic arthritis (PsA). TNF inhibitors have been demonstrated to improve the skin and joint manifestations of psoriasis. New possibilities of treatment of the disease have appeared due to availability of biological drugs which are TNF inhibitors. Among the first TNF inhibitors that have been used to treat PsA were etanercept, adalimumab, infliksymab. Due to primary and secondary ineffectiveness of the therapy occurring in large numbers of PsA patients investigations are going on in order to develop new, more effective, safer and more convenient methods to treat PsA. Such a new therapeutic possibility is offered by the new generation TNF inhibitor with a molecular structure different from other TNF inhibitors – certolizumab pegol (CZP).In this article the results of clinical studies concerning the application of CZP in PsA treatment are presented. |
|---|---|
| ISSN: | 0034-6233 2084-9834 |